Craig T Jordan
Overview
Explore the profile of Craig T Jordan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
9533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Jia A, You J, Zhuang Z, Wang Y, Liu T, et al.
Haematologica
. 2025 Jan;
PMID: 39781620
Not available.
2.
Ho T, LaMere M, Kawano H, Byun D, LaMere E, Chiu Y, et al.
bioRxiv
. 2024 Nov;
PMID: 39605740
Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons...
3.
Patel S, Moskop D, Jordan C, Pietras E
Semin Hematol
. 2024 Oct;
61(6):409-419.
PMID: 39472255
In work spanning several decades, extensive studies have focused on the properties of malignant stem cells that drive the pathogenesis of acute myeloid leukemia (AML). However, relatively little attention has...
4.
Stiff A, Fornerod M, Kain B, Nicolet D, Kelly B, Miller K, et al.
Nat Genet
. 2024 Oct;
56(11):2434-2446.
PMID: 39367245
Genomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically...
5.
Islam N, Reuben J, Dale J, Coates J, Sapiah K, Markson F, et al.
JMIR Cancer
. 2024 Aug;
10:e54740.
PMID: 39167784
Background: The treatment of acute myeloid leukemia (AML) in older or unfit patients typically involves a regimen of venetoclax plus azacitidine (ven/aza). Toxicity and treatment responses are highly variable following...
6.
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, et al.
Haematologica
. 2024 Jun;
110(1):103-116.
PMID: 38934082
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due, at least in part, to drug resistance of leukemia stem cells (LSC). Recent clinical evidence suggests that...
7.
Sahasrabudhe D, Liesveld J, Minhajuddin M, Singh N, Nath S, Kumar V, et al.
Sci Rep
. 2024 Jun;
14(1):12868.
PMID: 38834690
Acute myeloid leukemia (AML) is fatal in the majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that...
8.
Rodems B, Sharma S, Baker C, Kaszuba C, Ito T, Liesveld J, et al.
bioRxiv
. 2024 May;
PMID: 38798540
Signals from the microenvironment are known to be critical for development, sustaining adult stem cells, and for oncogenic progression. While candidate niche-driven signals that can promote cancer progression have been...
9.
Sheth A, Althoff M, Tolison H, Engel K, Amaya M, Krug A, et al.
Cancer Discov
. 2024 May;
14(10):1922-1939.
PMID: 38787341
Acute myeloid leukemia stem cells (LSCs) are uniquely reliant on oxidative phosphorylation (OXPHOS) for survival. Moreover, maintenance of OXPHOS is dependent on BCL-2, creating a therapeutic opportunity to target LSCs...
10.
Davis L, Walker Z, Reiman L, Parzych S, Stevens B, Jordan C, et al.
Clin Cancer Res
. 2024 May;
30(14):3023-3035.
PMID: 38723281
Purpose: Immunomodulatory drugs (IMiDs), such as lenalidomide and pomalidomide, are a cornerstone of multiple myeloma (MM) therapies, yet the disease inevitably becomes refractory. IMiDs exert cytotoxicity by inducing cereblon-dependent proteasomal...